Development | Vaccine | Therapeutic Vaccine Against 14 Oncogenic HPV Types
Therapeutic Vaccine Against 14 Oncogenic HPV Types
We have developed a novel human papillomavirus vaccine consisting of two circular DNA-based components: a therapeutic and a protective one, designed to provide both preventive and therapeutic effects against 14 high-risk oncogenic strains (HPV 16, 35, 58, 31, 18, 56, 45, 39, 51, 68, 59, 33, 52, 58). The vaccine is also effective against HPV types 6 and 11, which cause genital warts.
Therapeutic Component
Developed for treating severe or recurrent HPV infections (warts, condylomas, and cervical cancer), this component encodes a recombinant protein combining E7 protein sequences from multiple HPV strains to ensure comprehensive protection against all 14 targeted virus types. The vaccine also incorporates an intramolecular immune response enhancer (KDEL3), enabling the DNA vaccine to induce a robust and durable T-cell immune response.
Protective Component
Designed to establish long-lasting immunity against HPV, this component encodes a recombinant protein engineered from three conserved fragments of the HPV minor capsid protein L2, providing coverage against the same 14 virus strains. To amplify the immune response, the recombinant protein carries three copies of each selected L2 protein segment. This DNA vaccine induces both persistent T-cell and B-cell immune responses.
Therapeutic Vaccine Against 14 Oncogenic HPV Types
We have developed a novel human papillomavirus vaccine consisting of two circular DNA-based components: a therapeutic and a protective one, designed to provide both preventive and therapeutic effects against 14 high-risk oncogenic strains (HPV 16, 35, 58, 31, 18, 56, 45, 39, 51, 68, 59, 33, 52, 58). The vaccine is also effective against HPV types 6 and 11, which cause genital warts.
Therapeutic Component
Developed for treating severe or recurrent HPV infections (warts, condylomas, and cervical cancer), this component encodes a recombinant protein combining E7 protein sequences from multiple HPV strains to ensure comprehensive protection against all 14 targeted virus types. The vaccine also incorporates an intramolecular immune response enhancer (KDEL3), enabling the DNA vaccine to induce a robust and durable T-cell immune response.
Protective Component
Designed to establish long-lasting immunity against HPV, this component encodes a recombinant protein engineered from three conserved fragments of the HPV minor capsid protein L2, providing coverage against the same 14 virus strains. To amplify the immune response, the recombinant protein carries three copies of each selected L2 protein segment. This DNA vaccine induces both persistent T-cell and B-cell immune responses.
Leave your request, and we will contact you.
Would you like us to develop a custom drug?
Сообщение об успешной отправке!
Phone:
Email:
